Comprehensive review confirms that the Oncotype DX Breast Recurrence Score ® test accurately predicts breast cancer outcomes and chemotherapy benefit for patients regardless of race or ethnicity ...
REDWOOD CITY, Calif., March 25, 2019 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that new data presented at the 16th St. Gallen International Breast Cancer Conference in Vienna ...
New ASCO Recommendations Increase Proportion of Women Who Can Be Spared Chemotherapy Based on Landmark TAILORx and NSABP B-20 Randomized Clinical Trials Additional Secondary Analysis of TAILORx Trial ...
MADISON, Wis., April 28, 2022 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leader in advanced cancer diagnostics, today announced that recommended use of its Oncotype DX Breast Recurrence ...
Exact Sciences, a leading provider of cancer screening and diagnostic tests, today announced that the UK’s National Institute for Health and Care Excellence (NICE) has recommended the expanded use of ...
First clinical validation of the Oncodetect ® test to be presented in triple negative breast cancer; signals highly sensitive molecular residual disease (MRD) detection The Oncotype DX ® test is ...
Exact Sciences, a leading provider of cancer screening and diagnostic tests, today announced the presentation of new data further reinforcing the utility of its Oncotype DX Breast Recurrence Score(R) ...
The Oncotype DX test helps identify which women with early stage breast cancer whose cancer is estrogen-receptor-positive are more likely to benefit from adding chemo to their hormonal treatment. That ...
In what's believed to be one of the largest population-based studies of Oncotype DX ever conducted, researchers at The University of Texas MD Anderson Cancer Center have found that the commercial ...
Pertuzumab/Docetaxel/Carboplatin/Trastuzumab Regimen in Human Epidermal Growth Factor Receptor 2–Positive Early, Locally Advanced, and Oligometastatic Breast Cancer ...
Feb 5 (Reuters) - Genomic Health Inc: * ONCOTYPE DX® GENOMIC PROSTATE SCORE™ TEST INCREASES USE OF ACTIVE SURVEILLANCE BY 30 PERCENT IN LOW-RISK PATIENTS, RESULTING IN GREATER ADHERENCE TO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results